Literature DB >> 21656035

Doxycycline attenuates peripheral inflammation in rat experimental autoimmune neuritis.

Chenju Yi1, Zhiyuan Zhang, Wei Wang, Caroline Zug, Hermann J Schluesener, Zhiren Zhang.   

Abstract

Experimental autoimmune neuritis (EAN) is a T cell-mediated autoimmune inflammatory demyelinating disease of the peripheral nervous system and widely-used animal model of human inflammatory demyelinating polyradiculoneuropathies. Doxycycline is a well-known antibiotic and has been reported to have neuroprotective and anti-inflammatory effects. Here we investigated the effects of doxycycline on rat EAN. Therapeutic treatment with doxycycline (40 mg/kg body weight daily from the Day 9 to Day 14 post immunization) significantly attenuated the severity of EAN, decreased inflammatory infiltration of macrophages, B- and T-cells and demyelination in sciatic nerves of EAN rats. Pro-inflammatory molecules including matrixmetalloproteinase-9, inducible nitric oxide synthase and interleukin-17 were greatly decreased in sciatic nerves by administration of doxycycline as well. Taken together, our data showed that doxycycline could effectively suppress the peripheral inflammation to improve outcome of EAN, which suggests that doxycycline may be considered as a potential candidate of pharmacological treatment for neuropathies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21656035     DOI: 10.1007/s11064-011-0522-2

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  37 in total

Review 1.  New uses for older antibiotics: nitrofurantoin, amikacin, colistin, polymyxin B, doxycycline, and minocycline revisited.

Authors:  Burke A Cunha
Journal:  Med Clin North Am       Date:  2006-11       Impact factor: 5.456

2.  Effect of doxycycline on pre-menstrual syndrome: a double-blind randomized clinical trial.

Authors:  A Toth; M L Lesser; G Naus; C Brooks; D Adams
Journal:  J Int Med Res       Date:  1988 Jul-Aug       Impact factor: 1.671

3.  P0 myelin protein produces experimental allergic neuritis in Lewis rats.

Authors:  P Milner; C A Lovelidge; W A Taylor; R A Hughes
Journal:  J Neurol Sci       Date:  1987-07       Impact factor: 3.181

4.  Preoperative treatment with doxycycline reduces aortic wall expression and activation of matrix metalloproteinases in patients with abdominal aortic aneurysms.

Authors:  J A Curci; D Mao; D G Bohner; B T Allen; B G Rubin; J M Reilly; G A Sicard; R W Thompson
Journal:  J Vasc Surg       Date:  2000-02       Impact factor: 4.268

5.  Expression of constitutive endothelial and inducible nitric oxide synthase in the sciatic nerve of Lewis rats with experimental autoimmune neuritis.

Authors:  Yongduk Lee; Taekyun Shin
Journal:  J Neuroimmunol       Date:  2002-05       Impact factor: 3.478

6.  Doxycycline reduces cleaved caspase-3 and microglial activation in an animal model of neonatal hypoxia-ischemia.

Authors:  Lauren L Jantzie; Po-Yin Cheung; Kathryn G Todd
Journal:  J Cereb Blood Flow Metab       Date:  2005-03       Impact factor: 6.200

7.  A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results.

Authors: 
Journal:  Clin Neuropharmacol       Date:  2008 May-Jun       Impact factor: 1.592

8.  The use of protease inhibitors in experimental allergic neuritis.

Authors:  M Schabet; J N Whitaker; K Schott; A Stevens; A Zürn; R Bühler; H Wiethölter
Journal:  J Neuroimmunol       Date:  1991-03       Impact factor: 3.478

9.  Inducible nitric oxide synthase (iNOS) and endothelial nitric oxide synthase (eNOS) expression in fulminant hepatic failure.

Authors:  Ludger Leifeld; Magdalene Fielenbach; Franz-Ludwig Dumoulin; Nicola Speidel; Tilman Sauerbruch; Ulrich Spengler
Journal:  J Hepatol       Date:  2002-11       Impact factor: 25.083

10.  Improved outcome of EAN, an animal model of GBS, through amelioration of peripheral and central inflammation by minocycline.

Authors:  Zhi-Yuan Zhang; Zhiren Zhang; Uwe Fauser; Hermann J Schluesener
Journal:  J Cell Mol Med       Date:  2008-04-08       Impact factor: 5.310

View more
  6 in total

Review 1.  New strategies in the management of Guillain-Barré syndrome.

Authors:  Jinting Xiao; Alain R Simard; Fu-Dong Shi; Junwei Hao
Journal:  Clin Rev Allergy Immunol       Date:  2014-12       Impact factor: 8.667

2.  Effect of doxycycline and meloxicam on cytokines, brain-derived neurotrophic factor, matrix metalloproteinase-3, tissue inhibitor of metalloproteinase-3 and cyclooxygenase-2 in brain.

Authors:  Ayse Er; Devran Coskun; Emre Bahcivan; Burak Dik
Journal:  Iran J Basic Med Sci       Date:  2020-10       Impact factor: 2.699

3.  Tau overexpression impacts a neuroinflammation gene expression network perturbed in Alzheimer's disease.

Authors:  Paul D Wes; Amy Easton; John Corradi; Donna M Barten; Nino Devidze; Lynn B DeCarr; Amy Truong; Aiqing He; Nestor X Barrezueta; Craig Polson; Clotilde Bourin; Marianne E Flynn; Stefanie Keenan; Regina Lidge; Jere Meredith; Joanne Natale; Sethu Sankaranarayanan; Greg W Cadelina; Charlie F Albright; Angela M Cacace
Journal:  PLoS One       Date:  2014-08-25       Impact factor: 3.240

4.  Doxycycline, metronidazole and isotretinoin: Do they modify microRNA/mRNA expression profiles and function in murine T-cells?

Authors:  Eugenia Becker; Susan Bengs; Sirisha Aluri; Lennart Opitz; Kirstin Atrott; Claudia Stanzel; Pedro A Ruiz Castro; Gerhard Rogler; Isabelle Frey-Wagner
Journal:  Sci Rep       Date:  2016-11-17       Impact factor: 4.379

5.  Tetracyclines Diminish In Vitro IFN-γ and IL-17-Producing Adaptive and Innate Immune Cells in Multiple Sclerosis.

Authors:  Despoina T Florou; Athanasios Mavropoulos; Efthymios Dardiotis; Vana Tsimourtou; Vasileios Siokas; Athina-Maria Aloizou; Christos Liaskos; Christina Tsigalou; Christina Katsiari; Lazaros I Sakkas; Georgios Hadjigeorgiou; Dimitrios P Bogdanos
Journal:  Front Immunol       Date:  2021-11-26       Impact factor: 7.561

6.  Tetracyclines and neuromuscular disorders.

Authors:  Daniele Orsucci; Michelangelo Mancuso; Massimiliano Filosto; Gabriele Siciliano
Journal:  Curr Neuropharmacol       Date:  2012-06       Impact factor: 7.363

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.